Dicle İskender

Dr. Dicle İskender


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 August 2019 in The Journal of Infection in Developing Countries
Verified
Journal Article
Open access
PDF file
DMDuygu Mert
Duygu Mert
SCSabahat Ceken
Sabahat Ceken
GIGulsen Iskender
Gulsen Iskender
DİDicle İskender
Dicle İskender
AMAlparslan Merdin
Alparslan Merdin
FAFevzi Altuntas
Fevzi Altuntas
Introduction: Patients with hematological malignancies, who are in the high risk group for infectious complications and bacterial bloodstream infections. The aim of the study evaluated epidemiology and mortality in bacterial bloodstream infections in patients with hematologic malignancies. In addition to determine the risk factors, changes in the distribution and frequency of isolated bacterias. Methodology: In this retrospective study. There were investigated data from 266 patients with hematological malignancies and bacterial bloodstream infections who were hospitalized between the dates 01/01/2012 and 12/31/2017. Results: There were 305 blood and catheter cultures in febrile neutropenia attacks in total. In these total attacks, primary bloodstream infections were 166 and catheter-related bloodstream infections were 139. In blood cultures; Escherichia coli and Klebsiella pneumoniae bacteria were detected in 58,0% and 22,9% of the samples, respectively. 52,4% of the cultured Gram-negative bacterias were extended spectrum beta-lactamase (ESBL). Carbapenemase positive culture rate was 17,2% in Gram-negative bacteria cultures. Staphylococcus epidermidis was found in 38,4% of the Gram-positive bacteria cultures. In Gram-positive bacteria; methicillin resistance were detected in 82,2% of the samples. There was a statistically significant relationship between bloodstream infection and disease status. 60 patients with primary bloodstream infections were newly diagnosed. Conclusions: In patients with hematological malignancies, certain factors in the bloodstream infections increase the mortality rate. With the correction of these factors, the mortality rate in these patients can be reduced. The classification of such risk factors may be an important strategy to improve clinical decision making in high-risk patients, such as patients with hematological malignancies.

1 January 2022
Verified
Journal Article
Closed access
DİDicle İskender
Dicle İskender
MCM. K. Cakar
M. K. Cakar
MDM. S. Dal
M. S. Dal
NBN. A. Baysal
N. A. Baysal
AMA. Merdin
A. Merdin
FAF. Altuntas
F. Altuntas

31 August 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
EBErsin Bozan
Ersin Bozan
SYSamet Yaman
Samet Yaman
GBGökcen Bozan
Gökcen Bozan
MDMahmut Esad Durmuş
Mahmut Esad Durmuş
BCBurcu Aslan candir
Burcu Aslan candir
FAFevzi Altuntaş
Fevzi Altuntaş
Background/Objectives: In multiple myeloma, extramedullary involvement confers poor prognosis. Extramedullary involvement in multiple myeloma may manifest at the time of diagnosis or during a relapse, and it represents a severe condition. Patients with bone involvement are referred to as EM-B, while those with soft tissue involvement are referred to as EM-S. Although various studies have been conducted, the number of studies that categorize extramedullary involvement and examine the effects of flow cytometry, treatment, and genetic findings on prognosis is quite limited. We aimed to contribute to the literature by addressing this gap. Methods: In our study, we retrospectively examined the data of 281 patients followed at our center between 2011 and 2023. Clinical/laboratory data and flow cytometry profiles were collected. Survival was analyzed using Kaplan–Meier and Cox models; logistic regression was used for categorical variables. Hazard ratios (HRs), odds ratios (ORs), and 95% confidence intervals (CIs) were calculated; p-values were reported to three decimals. Results: Extramedullary involvement was absent in 134 (47.7%) patients, while involvement was detected in 147 (52.3%) patients. The median age of the patients was 60 years, and the median follow-up period was 35.4 months. No association was found between CD56 expression on plasma cells, higher Revised Multiple Myeloma International Staging System (R-ISS) score, and extramedullary involvement. Overall survival (OS) was found to be significantly lower in patients with extramedullary involvement. Conclusions: The findings of our study are consistent with many studies in the literature, supporting the finding that survival rates are lower in myeloma patients with extramedullary involvement. Further studies are needed to elucidate the pathogenesis in patients with extramedullary involvement in multiple myeloma and to provide a basis for targeted therapies. Studies involving immunotherapy and cellular therapies may offer a new avenue for these patients.

23 June 2021 in Journal of Obstetrics and Gynaecology
Verified
Journal Article
Closed access
OKOktay Kaymak
Oktay Kaymak
DİDicle İskender
Dicle İskender
NDNuri Danışman
Nuri Danışman
In the present study, we aimed to compare postprandial 90 minute measurements and postprandial 1 hour (PP1-HR) measurements for prediction of foetal growth disturbances and pregnancy complications. This was a prospective study conducted in Acıbadem Mehmet Ali Aydınlar University Altunizade Hospital in Department of Perinatology. The study group consisted of patients diagnosed with gestational diabetes. In each antepartum visit, the patients fasting plasma glucose as well as PP1-HR and 90 minute measurements were made. Perinatal and neonatal data were obtained from each patient. The rate of large for gestational age infants was increased in patients when either PP1-HR measurement above 140 mg/dl or postprandial 90 minute measurement above 165 mg/dl compared to patients with normal PP1-HR or postprandial 90 minute measurement. Preterm delivery rate was increased in patients with postprandial 90 minute measurement above 165 mg/dl but not in patients with PP1-HR measurement above 140 mg/dl. The optimal cut-off for postprandial 90 minute measurement was 165 mg/dl based on receiver operating characteristics curve. Our preliminary data show that postprandial 90 minute measurements are superior to PP1-HR measurements in predicting large for gestational age infants.

25 March 2026 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
SSSema Seçilmiş
Sema Seçilmiş
BCBurcu Aslan candir
Burcu Aslan candir
UHUgur Hatipoglu
Ugur Hatipoglu
Mert SeyhanMert Seyhan
Mert Seyhan
BUBahar Uncu Ulu
Bahar Uncu Ulu
FAFevzi Altuntaş
Fevzi Altuntaş
Background/Objectives: Allogeneic hematopoietic stem cell transplantation is associated with increased cardiovascular risk driven by endothelial dysfunction, chronic inflammation, and treatment-related metabolic disturbances, including dyslipidemia. In the contemporary era of post-transplant cyclophosphamide-based prophylaxis, the prognostic significance of dyslipidemia—particularly as assessed by non-HDL cholesterol—remains unclear. In this study, we aimed to compare the engraftment days, graft-versus-host disease (GVHD) development, relapse, overall survival rates, and cardiovascular mortality in patients using myeloablative/reduced intensity conditioning regimens with post-transplant cyclophosphamide (PTCy) 50 mg/kg/day for 2 days in patients with acute leukemias. Methods: A total of 95 adult patients with acute leukemias were included in their first remission who underwent matched sibling donor transplantation with PTCy (50 mg/kg on days +3 and +4). Patients were stratified according to pre-transplant non-HDL-C levels (<160 mg/dL vs. ≥160 mg/dL). Matched related donors were selected for the patients. All patients received either myeloablative or reduced-intensity conditioning based on EBMT criteria, with fludarabine-based combinations including busulfan, treosulfan, or TBI, along with ATLG administered at a total dose of 15 mg/kg. Peripheral blood stem cells were used for all transplants, and GVHD prophylaxis consisted of cyclosporine. Results: Platelet (median 13 vs. 14 days) and neutrophil (median 14 vs. 15 days) engraftment times and veno-occlusive disease (VOD) rates were comparable across groups (all p > 0.05); cumulative incidences of grade II–IV aGVHD at +100 days, grade III–IV aGVHD at +100 days, and moderate-severe cGVHD at 1 year, relapse-free survival, and non-relapse mortality at 1 year were comparable in two cohorts (all p > 0.05). GVHD-free/relapse-free survival (GRFS) at 1 year was also comparable across groups (p = 0.15). Median GRFS was 150 (95% CI: 120–330) days and 270 (95% CI: 154-not reached) days, respectively [HR was 0.68 (0.40–1.15), p = 0.15; GRFS at 1 year was 66.6% vs. 52.0%, respectively]. The groups were also comparable in terms of overall survival (OS). Follow-up ranged from 0.5 to 108 months, and median follow-up was 60 months in two cohorts. Median OS was not reached in non-HDL-C < 160 (95% CI: 70 months–not reached) and 67 months in non-HDL-C ≥ 160 groups (95% CI: 13 months–not reached) (Log rank = 0.21). No cardiovascular death events occurred during the follow-up period. Conclusions: In this homogeneous matched sibling donor transplant cohort with extended follow-up and uniform administration of post-transplant cyclophosphamide, cyclosporine-based GVHD prophylaxis, and anti-thymocyte lymphoglobulin (ATLG), pre-existing dyslipidemia was not associated with an adverse impact on GRFS, NRM, PFS, CMV reactivation, OS or long-term cardiovascular mortality.

4 September 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
SSSema Seçilmiş
Sema Seçilmiş
BCBurcu Aslan candir
Burcu Aslan candir
EBErsin Bozan
Ersin Bozan
SYSamet Yaman
Samet Yaman
BUBahar Uncu Ulu
Bahar Uncu Ulu
FAFevzi Altuntaş
Fevzi Altuntaş
Background/Objectives: Hematopoietic stem cell (HSCs) mobilization from the bone marrow to the peripheral blood (PB) is a critical step in stem cell transplantation. Although some experimental studies have suggested that cholesterol levels may affect this process, the clinical relevance of lipid profiles in healthy donors remains unclear. This study aimed to investigate whether serum cholesterol parameters are associated with peripheral blood CD34+ HSC mobilization in healthy stem cell donors. Methods: A total of 251 healthy donors who underwent granulocyte colony-stimulating factor (G-CSF)-based mobilization were retrospectively analyzed. Peripheral blood CD34+ cell counts and yields (×106/kg) were recorded. Laboratory parameters, including total cholesterol, HDL-C, LDL-C, and triglyceride levels were evaluated. Correlations between mobilization outcomes and donor characteristics or laboratory findings were also assessed. Results: No significant association was found between serum lipid parameters (total cholesterol, LDL-C, HDL-C, triglycerides) and CD34+ cell mobilization or yield. However, white blood cell count, hemoglobin level, platelet count, absolute neutrophil count, and lymphocyte count showed significant positive associations with mobilization efficacy. In contrast, body mass index (BMI) was inversely correlated with CD34+ cell yield. Conclusions: Serum cholesterol levels do not appear to influence stem cell mobilization outcomes in healthy donors. Classical hematologic parameters remain reliable predictors of CD34+ cell yield. These findings suggest that cholesterol is not a suitable biomarker for predicting mobilization efficiency in this population group.